working at the interface of synthetic chemistry, biochemistry and proteomics

Our laboratory is interested in the discovery of new cysteine-reactive small molecules with intriguing biomedical activities using chemical proteomics platforms (chemoproteomics-enabled drug discovery).

Cysteines with enhanced nucleophilicity (so-called hyperreactive cysteines) are found in diverse families of enzymes of biomedical importance such as proteases, kinases and oxidoreductases and, intriguingly, also on protein classes that are traditionally considered ‘undruggable’. Hyperreactive cysteines can be chemoselectively modified with moderately reactive electrophilic probes such as haloacetamides and α,β-unsaturated carbonyl compounds and this creates an opportunity for the development of novel pharmacological agents capable of selectively interfering with the activity of ‘undruggable’ proteins.

Our laboratory is interested in the discovery of new cysteine-reactive small molecules with intriguing biomedical activities using chemical proteomics platforms (chemoproteomics-enabled drug discovery). We are especially interested in identification of small molecules that target functional cysteines on proteins with proven oncogenic activity that are currently considered ‘undruggable’.

Illustration of Adibekian lab